| Literature DB >> 28810889 |
Ming-Hung Tsai1, Hui-Chun Huang2,3,4, Yun-Shing Peng5,6, Yung-Chang Chen6,7, Ya-Chung Tian6,7, Chih-Wei Yang6,7, Jau-Min Lien1, Ji-Tseng Fang6,7, Cheng-Shyong Wu6,8, Sen-Yung Hsieh1, Fa-Yauh Lee9,10.
Abstract
BACKGROUND: Cirrhotic patients are susceptible to sepsis and critical illness-related corticosteroid insufficiency (CIRCI). Dehydroepiandrosterone sulfate (DHEAS) is a corticotropin-dependent adrenal androgen, which has immunostimulating and antiglucocorticoid effects. Considering the synchronized synthesis of cortisol and DHEAS and their opposing effects to each other, investigators have proposed measuring these two hormones as a ratio. Severe sepsis has been associated with low DHEAS, especially relative to high cortisol. Despite growing interest in the role of adrenal androgen replacement in critical illness, there have been no data about DHEAS and the DHEAS/cortisol ratio in patients with liver cirrhosis. We studied whether low concentrations of DHEAS and decreased DHEAS/cortisol ratio are associated with poor outcome in patients with liver cirrhosis and septic shock.Entities:
Keywords: Adrenal androgen; Cirrhosis; Sepsis; Steroidogenesis
Mesh:
Substances:
Year: 2017 PMID: 28810889 PMCID: PMC5557480 DOI: 10.1186/s13054-017-1768-0
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Patients’ demographic data and clinical characteristics at admission to the ICU grouped according to hospital mortality
| Hospital survivors ( | Hospital nonsurvivors ( |
| |
|---|---|---|---|
| Age (years) | 47.6 ± 14.8 | 58.8 ± 14.3 | 0.029 |
| Gender (M/F) | 11/1 | 25/9 | 0.252 |
| SOFA score | 8.3 ± 2.5 | 14.0 ± 3.6 | <0.001 |
| MELD score | 20.9 ± 10.7 | 33.0 ± 9.9 | 0.001 |
| Child–Pugh score | 10 (7.3–11.8) | 12 (11–13.3) | 0.005 |
| ACTH (pg/ml) | 8.7 (7.5–25.5) | 20.7 (13.1–35.1) | 0.084 |
| Baseline cortisol (nmol/L) | 484 (381–796) | 821 (508–1312) | 0.026 |
| Peak cortisol (nmol/L) | 955 (633–1258) | 993 (807–1549) | 0.354 |
| Cortisol increment (nmol/L) | 359 (257–428) | 200 (110–252) | 0.011 |
| Baseline DHEAS (nmol/L) | 1099 (787–2627) | 622 (403–1006) | 0.002 |
| Peak DHEAS (nmol/L) | 1286 (1118–2874) | 699 (429–1115) | <0.001 |
| DHEAS increment (nmol/L) | 236 (179–391) | 41 (10–96) | <0.001 |
| Baseline DHEAS/cortisol ratio | 2.86 ± 1.40 | 0.92 ± 0.73 | 0.001 |
| IL-6 (pg/ml) | 110 (54–233) | 571 (247.25–924) | 0.004 |
| TNF-α (pg/ml) | 10 (5.5–25) | 45.5 (31.25–78.25) | 0.001 |
Data presented as mean ± SD, number, or median (interquartile range)
M male, F female, SOFA Sequential Organ Failure Assessment, MELD Model for End-Stage Liver Disease, ACTH adrenocorticotropic hormone, DHEAS dehydroepiandrosterone sulfate, IL-6 interleukin-6, TNF-α tumor necrosis factor alpha, ICU intensive care unit
Fig. 1Results of SSTs. a Levels of baseline cortisol are significantly higher in nonsurvivors. b Levels of baseline DHEAS are significantly higher in survivors. c Baseline DHEAS/cortisol ratios are significantly higher in survivors. d Cortisol increments upon challenge of ACTH are significantly higher in survivors. e DHEAS increments upon challenge of ACTH are significantly higher in survivors. Results expressed as median, error bars representing the interquartile range, in a, b, d, e. Results expressed as mean, error bars representing the standard deviation, in c. *p < 0.05, **p < 0.01, ***p < 0.001. DHEAS dehydroepiandrosterone sulfate
Baseline DHEAS and DHEAS/cortisol ratio to predict hospital survival
| Sensitivity | Specificity | PPV | NPV | Accuracy | |
|---|---|---|---|---|---|
| DHEAS | 0.818 | 0.647 | 0.429 | 0.917 | 0.689 |
| DHEAS/cortisol | 0.909 | 0.842 | 0.625 | 0.966 | 0.844 |
DHEAS dehydroepiandrosterone sulfate, PPV positive predictive value, NPV negative predictive value
Patients’ demographic data and clinical characteristics grouped according to baseline DHEAS/cortisol ratio
| High DHEAS/cortisol ratio (>1.50) ( | Low DHEAS/cortisol ratio (<1.50) ( |
| |
|---|---|---|---|
| Age (years) | 48.7 ± 11.4 | 60.2 ± 15.2 | 0.010 |
| Gender (M/F) | 15/2 | 21/8 | 0.282 |
| Hospital mortality | 6/17 (35.3%) | 28/29 (96.6%) | <0.001 |
| SOFA score | 10.8 ± 4.5 | 13.6 ± 3.7 | 0.030 |
| MELD score | 26.1 ± 12.7 | 32.1 ± 10.0 | 0.082 |
| Child–Pugh score | 12 (8–12.5) | 12 (11–13.5) | 0.106 |
| ACTH (pg/ml) | 19 (7.8–27.2) | 20.4 (10.8–38) | 0.372 |
| Baseline cortisol (nmol/L) | 441 (382–691) | 910 (661–1422) | 0.001 |
| Peak cortisol (nmol/L) | 822 (608–1141) | 1048 (902–1671) | 0.006 |
| Cortisol increment (nmol/L) | 273 (189–403) | 196 (97–288) | 0.037 |
| Baseline DHEAS (nmol/L) | 1099 (885–2124) | 551 (362–769) | <0.001 |
| Peak DHEAS (nmol/L) | 1286 (974–2546) | 643 (360–1057) | <0.001 |
| DHEAS increment (nmol/L) | 135.7 (88.2–248.3) | 35.3 (6.8–118.1) | 0.009 |
| IL-6 (pg/ml) | 198 (58.5–444) | 571 (221–1012) | 0.025 |
| TNF-α (pg/ml) | 17.6 (8.4–32.3) | 47.5 (30–96.8) | 0.002 |
| CIRCI | 7/17 (41.2%) | 21/29 (72.4%) | 0.036 |
Data presented as mean ± SD, number (percentage), or median (interquartile range)
M male, F female, SOFA Sequential Organ Failure Assessment, MELD Model for End-Stage Liver Disease, ACTH adrenocorticotropic hormone, DHEAS dehydroepiandrosterone sulfate, IL-6 interleukin-6, TNF-α tumor necrosis factor alpha, CIRCI critical illness-related corticosteroid deficiency
Patients’ demographic data, clinical characteristics at admission to ICU and outcomes grouped according to the SST
| CIRCI ( | Non-CIRCI ( |
| |
|---|---|---|---|
| Age (years) | 56.0 ± 12.8 | 56.0 ± 18.0 | 0.997 |
| Gender (M/F) | 22/6 | 14/4 | 1.000 |
| SOFA score | 14.8 ± 3.3 | 8.7 ± 2.8 | <0.001 |
| MELD score | 35.3 ± 8.8 | 21.3 ± 9.5 | <0.001 |
| Child–Pugh score | 13 (12–14) | 9 (8–11.5) | <0.001 |
| ACTH (pg/ml) | 28 (15–40) | 7.9 (6.7–18.3) | <0.001 |
| Baseline cortisol (nmol/L) | 877 (481–1331) | 555 (417–859) | 0.054 |
| Peak cortisol (nmol/L) | 967 (695–1505) | 1021 (803–1458) | 0.727 |
| Cortisol increment (nmol/L) | 145 (70–217) | 399 (314–546) | <0.001 |
| Baseline DHEAS (nmol/L) | 678 (437–1111) | 921 (524–1552) | 0.229 |
| Peak DHEAS (nmol/L) | 750 (491–1141) | 1159 (595–1866) | 0.075 |
| DHEAS increment (nmol/L) | 41 (16–101) | 180 (90–278) | 0.002 |
| Baseline DHEAS/cortisol | 1.01 ± 0.79 | 2.11 ± 1.58 | 0.012 |
| IL-6 (pg/ml) | 660 (240–968) | 164 (85–328) | 0.011 |
| TNF-α (pg/ml) | 44 (31–79) | 16 (6–36) | 0.007 |
| Hospital mortality | 26/28 (92.9%) | 8/18 (44.4%) | <0.001 |
Data presented as mean ± SD, number (percentage), or median (interquartile range)
M male, F female, SST short corticotropin stimulation test, CIRCI critical illness-related corticosteroid deficiency, SOFA Sequential Organ Failure Assessment, MELD Model for End-Stage Liver Disease, ACTH adrenocorticotropic hormone, DHEAS dehydroepiandrosterone sulfate, IL-6 interleukin-6, TNF-α tumor necrosis factor alpha, ICU intensive care unit
Fig. 2a Baseline DHEAS/cortisol ratio is negatively correlated to SOFA score (R = –0.440, p = 0.002). b Baseline DHEAS/cortisol ratio is negatively correlated to IL-6 (R = –0.503, p = 0.005). SOFA Sequential Organ Failure Assessment, DHEAS dehydroepiandrosterone sulfate, IL6 interleukin-6
Comparison between cirrhotic and noncirrhotic groups matched according to age and sex
| Liver cirrhosis ( | Nonliver cirrhosis ( |
| |
|---|---|---|---|
| Age (years) | 56.0 ± 14.9 | 58.1 ± 20.5 | 0.556 |
| Gender (M/F) | 36/10 | 36/10 | 1.000 |
| SOFA score | 12.7 ± 4.1 | 6.7 ± 4.1 | <0.001 |
| Baseline cortisol (nmol/L) | 748 (450–1203) | 778 (590–1109) | 0.628 |
| Peak cortisol (nmol/L) | 993 (744–1479) | 1195 (948–1589) | 0.041 |
| Cortisol increment (nmol/L) | 221 (121–348) | 408 (285–570) | <0.001 |
| ACTH (pg/ml) | 19.1 (9.1–34.0) | 20.3 (8–30.5) | 0.842 |
| Baseline DHEAS (nmol/L) | 703 (464–1180) | 842 (587–1432) | <0.001 |
| Peak DHEAS (nmol/L) | 939 (497–1296) | 1037 (643–1752) | <0.001 |
| DHEAS increment (nmol/L) | 89.6 (23–185) | 325.7 (174–546) | <0.001 |
| Baseline DHEAS/cortisol | 1.40 ± 1.24 | 3.86 ± 2.57 | 0.001 |
| IL-6 (pg/ml) | 424 (206–855) | 88 (35–275) | 0.002 |
| TNF-α (pg/ml) | 34 (21–70) | 15 (10.65–23.5) | 0.003 |
| Hospital mortality | 34/46 (73.9%) | 16/46 (34.8%) | <0.001 |
Data presented as mean ± SD, number (percentage), or median (interquartile range)
M male, F female, SOFA Sequential Organ Failure Assessment, ACTH adrenocorticotropic hormone, DHEAS dehydroepiandrosterone sulfate, IL-6 interleukin-6, TNF-α tumor necrosis factor alpha
Patients’ demographic data and clinical characteristics at admission to ICU grouped according to gender
| Male ( | Female ( |
| |
|---|---|---|---|
| Age (years) | 52.9 ± 12.6 | 67.0 ± 17.9 | 0.007 |
| Hospital mortality | 25/36 (69.4%) | 9/10 (90%) | (0.252) |
| SOFA score | 12.2 ± 4.4 | 13.0 ± 4.2 | (0.618) |
| MELD score | 30.5 (24–39.8) | 27 (16.8–37.8) | (0.431) |
| Child–Pugh score | 12 (10.3–13) | 11.5 (9–13.3) | (0.666) |
| ACTH (pg/ml) | 19.1 (9.8–32.7) | 22 (6.3–47.9) | (0.929) |
| Baseline cortisol (nmol/L) | 675 (428–1086) | 975 (680–1260) | (0.132) |
| Peak cortisol (nmol/L) | 927 (697–1381) | 1338 (955–1639) | (0.088) |
| Cortisol increment (nmol/L) | 221 (112–353) | 240 (167–466) | (0.432) |
| Baseline DHEAS (nmol/L) | 704 (437–1140) | 824 (510–1428) | (0.409) |
| Peak DHEAS (nmol/L) | 877 (491–1263) | 961 (510–1692) | (0.489) |
| DHEAS increment (nmol/L) | 89.6 (25.8–171.7) | 70.6 (0–245.7) | (0.957) |
| Baseline DHEAS/cortisol ratio | 1.46 ± 1.16 | 1.37 ± 1.68 | (0.843) |
| IL-6 (pg/ml) | 318 (150–855) | 482 (310–1288) | (0.404) |
| TNF-α (pg/ml) | 31 (11.2–78) | 47 (39–52.5) | (0.208) |
| CIRCI | 22/36 (61.1%) | 6/10 (60%) | (1.000) |
Data presented as mean ± SD, number (percentage), or median (interquartile range)
SOFA Sequential Organ Failure Assessment, MELD Model for End-Stage Liver Disease, ACTH adrenocorticotropic hormone, DHEAS dehydroepiandrosterone sulfate, IL-6 interleukin-6, TNF-α tumor necrosis factor alpha, CIRCI critical illness-related corticosteroid deficiency, ICU intensive care unit